Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis
This study has been terminated.
(Primary endpoint (heat shock proteins) cannot be analyzed with the described laboratory method as specified in the protocol.)
Sponsor:
Christoph Aufricht
Information provided by (Responsible Party):
Christoph Aufricht, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01353638
First received: May 5, 2011
Last updated: June 12, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | May 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |